BrainScope brings on ex-Greatbatch corp dev prez Holman as CCO
BrainScope said last week it appointed Andrew Holman as its chief commercial officer as the company approaches the launch of its 1st product.
Holman most recently served as prez of corporate development with Greatbatch (NYSE:GB), holding prior roles as chief commercial officer and exec veep of global sales and marketing with the company.
Prior to his time at Greatbatch, Holman served as exec veep of U.S. commercial business at DJO Global.
“We are delighted to welcome Andrew to the BrainScope team. This is a key hire for BrainScope as we prepare to bring our 1st product to market. Andrew has extensive experience in the key focus areas of medical device sales, strategic marketing and planning, business development, pricing and reimbursement. He has been highly successful in building high-performing commercial sales and marketing teams, both domestically and internationally. His well-rounded experience and enthusiasm makes him the perfect person to take us to the next level,” CEO Michael Singer said in a press release.
“I am thrilled and honored to join the BrainScope organization and serve in this critical role. I am very impressed with the company’s leadership and vision. I have a passion for traumatic brain injury and diseases of the central nervous system ever since my years at Johnson & Johnson, and believe that BrainScope is exceptionally well positioned to leverage its technological innovation in becoming the new standard of care in the assessment of TBI,” Holman said in a prepared statement.